You are viewing an archive version of the PSNC website taken on 18th April 2013. This site is not updated, and may be out of date or relate to old NHS structures.
For updated and current information, please visit our new website at www.psnc.org.uk
Skip Navigation
PSNC Home Page
Advanced Search
.

Pharmaceutical Services Negotiating Committee

Service evaluation, NMS statistics and PharmOutcomes data

Evaluation of the service

Following the publication by the Department of Health of an Invitation To Tender (ITT) in respect of evaluating the NMS, a team led by The University of Nottingham in collaboration with University College London and Warwick Business School won the contract to undertake the evaluation.

Download the ITT

Further information on the NMS evaluation

NMS evaluation website


PharmOutcomes data

Evidence taken from the PharmOutcomes platform has proven the impact the New Medicine Service (NMS) is having on medicines adherence and in doing so provided key evidence to be used to help persuade the Government and Department of Health of the value in commissioning it beyond April 2013.

An analysis was carried out by Gary Warner, chair of PSNC’s service development subcommittee, on PharmOutcomes data covering NMS interventions provided to more than 224,000 patients between 1st October 2011 and 30th September 2012.

The analysis found that 31.9% of non-adherent patients became adherent to 31.5% of their medicines after the NMS intervention. It also showed that pharmacists gave 366,702 pieces of healthy living advice to patients while they provided the service.

Other key findings from the analysis included that:

  • 99.6% of NMS patients were recruited directly by pharmacies, with the remainder referred by GP practices. In some areas the GP referral levels were much higher;
  • 54.4% of NMS interventions were provided for patients prescribed medicines for hypertension, with 26.4% asthma/COPD, 11.3% diabetes and 7.9% anticoagulants/antiplatelet medicines;
  • Patients very rarely withdrew their consent to receive the service at the intervention stage;
  • Patients on asthma and COPD medicines had the lowest incidence of side-effects, but those side-effects caused non-adherence at nearly twice the rate than in the other disease states.

Summary report on the PharmOutcomes NMS data (Nov 2012)

Full report on the PharmOutcomes NMS data (Nov 2012)

Errata notice


PharmOutcomes monthly data

A monthly summary of data extracted from the PharmOutcomes NMS module is available via the link below:

November 2012 PharmOutcomes NMS data summary

December 2012 PharmOutcomes NMS data summary

Data presented at a PSNC region level is available via the links below:

November 2012

East Anglia East Mids and S Yorks East Mersey
North East North Thames North West South Central
South East Coast South Thames South West West Midlands
Yorks and Humber      

December 2012

East Anglia East Mids and S Yorks East Mersey
North East North Thames North West South Central
South East Coast South Thames South West West Midlands
Yorks and Humber      

 


NMS statistics

Statistics on the provision of the NMS are available here.

 

 

Return to the main NMS page